English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, March 9, 2022
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
Monday, March 7, 2022
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得
Friday, March 4, 2022
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab
Friday, February 25, 2022
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Friday, February 4, 2022
エーザイ、人事異動を発表
Tuesday, February 1, 2022
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
エーザイ、コーポレートガバナンス・オブ・ザ・イヤー 2021「東京都知事賞」を受賞
Monday, January 31, 2022
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、進行性腎細胞がん一次療法として台湾において承認を取得

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575